Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review.
Hematology
; 29(1): 2399362, 2024 Dec.
Article
en En
| MEDLINE
| ID: mdl-39279268
ABSTRACT
INTRODUCTION:
Acute promyelocytic leukemia (APL) is mainly due to the chromosome translocation t(15; 17) (q22; q12), leading to the formation of PML-RARα fusion protein. However, some patients carried rare translocation involving RARα gene, and they were referred to as variant APL caused by the RAR family (RARα, RARB, and RARG) and partner genes. PLZF-RARα was a rare type of molecular genetic abnormality with unfavorable prognosis that has been reported in few cases in variant APL. Knowledge of PLZF-RARα (+) APL treatment remains limited understood. CASE REPORT We presented a case of variant APL in a 47-year-old female, who was PLZF-RARα positive detected by reverse transcription polymerase chain reaction (RT-PCR). The patient did not respond to all-trans retinoic acid (ATRA), idarubicin, and arsenic trioxide (As2O3) combined induction chemotherapy. Then, the patient was treated with Venetoclax combining with decitabine as the salvage therapy and achieved morphological remission and PLZF/RARα gene negative.CONCLUSION:
Venetoclax combining with decitabine can be used as an effective therapy in the PLZF-RARα positive APL.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sulfonamidas
/
Leucemia Promielocítica Aguda
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Proteínas de Fusión Oncogénica
/
Compuestos Bicíclicos Heterocíclicos con Puentes
/
Decitabina
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Hematology
Asunto de la revista:
HEMATOLOGIA
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Reino Unido